LDN therapy uses naltrexone, a drug originally approved to treat opioid and alcohol addiction, at a fraction of its standard dose to reduce inflammation and chronic pain. Where the full dose ranges from 50 to 100 mg, LDN typically falls between 0.1 and 4.5 mg per day. At these low doses, naltrexone appears to work through entirely different pathways than it does at higher doses, which is why it has attracted interest for conditions ranging from fibromyalgia to autoimmune diseases.
How LDN Works in the Body
Naltrexone at full doses blocks opioid receptors around the clock, which is how it helps people with addiction resist the effects of opioids or alcohol. At low doses, the blockade is brief, lasting only a few hours. The body responds to this short interruption by ramping up production of its own natural pain-relieving molecules (endorphins) and by increasing the sensitivity of opioid receptors. Think of it as a brief challenge that triggers a compensatory rebound, leaving the system more responsive to its own built-in pain relief once the drug clears.
At the cellular level, LDN interacts with a system called the opioid growth factor pathway. It increases production of both the opioid growth factor (a natural compound involved in regulating cell growth) and its receptor. This pathway helps regulate how cells proliferate, which is one reason researchers have explored LDN in conditions involving abnormal immune cell activity.
LDN also appears to calm inflammation directly. Immune cells in the brain and spinal cord called microglia act as the nervous system’s first responders. When they become overactivated, they drive chronic neuroinflammation, which contributes to pain and fatigue. LDN shifts these cells from a pro-inflammatory state to a quieter, anti-inflammatory mode by interfering with a specific receptor (toll-like receptor 4) on their surface. This shift changes how the cells generate energy, moving them into a lower, more controlled metabolic state. The net result is less inflammatory signaling in the nervous system.
Conditions LDN Is Used For
Fibromyalgia
Fibromyalgia is one of the most studied applications for LDN. The condition involves widespread pain, fatigue, and heightened sensitivity to stimuli, all of which overlap with the neuroinflammatory processes LDN targets. Systematic reviews of fibromyalgia trials show that patients with higher baseline markers of inflammation tend to respond better to LDN, with some achieving at least a 30% reduction in symptoms. The evidence is still building, and not every patient responds, but LDN has become a commonly prescribed off-label option for fibromyalgia when standard treatments fall short.
Crohn’s Disease
In a placebo-controlled trial of adults with Crohn’s disease, 83% of patients taking LDN showed meaningful clinical improvement at 12 weeks, compared to 38% on placebo. The effect was also visible on endoscopy: 72% of LDN patients showed measurable healing of the intestinal lining versus 25% on placebo. Full clinical remission rates were more modest (30% on LDN versus 18% on placebo), and that difference wasn’t statistically significant. Still, the improvement in symptoms and visible gut healing has kept Crohn’s disease on the map as a promising application.
Multiple Sclerosis
LDN has a following among people with multiple sclerosis, particularly for managing fatigue and quality of life. However, the clinical evidence is less convincing here. A randomized placebo-controlled trial found no meaningful difference between LDN and placebo across pain, energy, emotional well-being, cognitive function, or overall quality of life in patients with relapsing-remitting and secondary progressive MS. The study did confirm that LDN was safe and well tolerated in this population, but its effectiveness for MS specifically remains uncertain.
Other Chronic Pain Conditions
Clinicians prescribe LDN off-label for a range of other chronic pain and autoimmune conditions, including complex regional pain syndrome, rheumatoid arthritis, and chronic fatigue syndrome. The evidence base for most of these is limited to small studies and clinical observation rather than large trials.
Dosing and How Treatment Starts
There is no universally agreed-upon dose, which is part of why LDN remains outside mainstream treatment guidelines. Most patients end up somewhere between 1.5 and 4.5 mg per day, with 4.5 mg being the most commonly cited target dose for chronic pain. But effective doses have been documented as low as 0.1 mg.
Treatment typically starts at the lowest dose (0.1 mg per day) and increases by 0.1 mg every three days. This slow titration helps identify the dose that provides the best symptom relief with the fewest side effects, since individual responses vary widely. If no improvement has occurred by 6 mg per day, the trial is generally discontinued. Some practitioners also use ultra-low doses below 0.001 mg for specific purposes, such as easing opioid withdrawal, though this is a separate application from standard LDN therapy.
Why You Need a Compounding Pharmacy
Naltrexone is commercially available only in 50 mg tablets, designed for addiction treatment. No manufacturer sells the drug in the tiny doses needed for LDN. That means your prescription must be filled by a compounding pharmacy, which prepares the medication to your specific dose.
At such small amounts (often less than 5 mg), the active ingredient would be essentially invisible on a spoon. Compounding pharmacies mix naltrexone with fillers to scale the dose up to a size that can be accurately measured and handled. These fillers also help preserve stability so the medication doesn’t degrade within days. Common forms include capsules, which tend to have the fewest additives, and sublingual liquids, which offer the most flexibility for dose adjustments. If you have sensitivities to lactose or other common inactive ingredients, it’s worth discussing filler options with your pharmacist, as formulations vary.
Because LDN requires compounding, insurance coverage is inconsistent. Many patients pay out of pocket, though the cost is generally modest compared to other chronic disease medications.
Side Effects
LDN is widely described as well tolerated, and serious side effects are rare. The most commonly reported issue is unusually vivid dreams, particularly in the first weeks of treatment. It’s worth noting that vivid dreams are also the most frequently reported side effect during placebo administration in clinical trials, so some of this effect may be driven by expectation.
Headaches occur slightly more often on LDN than on placebo, though the difference hasn’t reached statistical significance in the studies conducted so far. Some physicians have reported anxiety and rapid heart rate in individual patients, but these haven’t been observed consistently in formal research. Most side effects diminish over the first few weeks as the body adjusts.
Critical Interactions With Opioid Medications
LDN cannot be taken alongside opioid pain medications, and this is not a minor caution. Because LDN increases the number and sensitivity of opioid receptors over time, taking even a small dose of an opioid painkiller can produce a dangerously amplified response. In one documented case, a patient on LDN for multiple sclerosis received a single 5 mg dose of oxycodone, a routine amount for pain management, and became so deeply sedated that naloxone rescue and an overnight intensive care stay were required.
This interaction extends to all opioid-based medications: morphine, codeine, fentanyl, buprenorphine, methadone, and others. If you are transitioning from opioid therapy to LDN, a washout period of at least ten days off opioids is recommended before starting naltrexone. Taking them together risks either precipitating withdrawal symptoms or, paradoxically, causing opioid hypersensitivity. This is something any prescribing clinician should discuss in detail before beginning treatment.
How to Access LDN
LDN is a prescription medication, but because its uses for chronic pain and autoimmune conditions are off-label, not every physician is familiar with it or willing to prescribe it. Integrative medicine practitioners, pain specialists, and some rheumatologists are the most likely to have experience. Patient advocacy organizations, such as the LDN Research Trust, maintain directories of prescribers and compounding pharmacies.
Because the evidence base consists mostly of small trials and observational studies, LDN occupies an unusual space: promising enough that thousands of clinicians prescribe it, but not yet supported by the large-scale trials that would lead to formal regulatory approval for these conditions. For patients who have exhausted first-line treatments, that trade-off between limited formal evidence and a favorable safety profile is often what makes LDN worth trying.